Physician profile
Christopher A Lambert
NPI 1063801983
$35,152.60
in general payments reported to CMS, 2019-2025
44 companies · $2,973 in 2025
The $2,973 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $7,534 · 2022: $11K · 2023: $9,450 · 2024: $3,807 · 2025: $2,973.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,167 · Consulting Fee: $3,575 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,575 · Travel and Lodging: $2,912.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,167.04 |
| Consulting Fee | $3,575.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,575.00 |
| Travel and Lodging | $2,912.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $26,618.73 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $2,786.98 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $859.16 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $555.98 | 2021-2025 | Tezspire, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $429.05 | 2021-2024 | |
| Novo Nordisk INC | $383.68 | 2021-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $376.98 | 2021-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Idorsia Pharmaceuticals US INC | $308.79 | 2022-2025 | Quviviq, Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $260.55 | 2021-2024 | Trintellix |
| Biohaven Pharmaceutical Holding Company Ltd. | $215.83 | 2022 | |
| Phathom Pharmaceuticals, INC. | $206.59 | 2024 | Voquezna |
| Incyte Corporation | $200.42 | 2023 | Opzelura |
| Merck Sharp & Dohme LLC | $193.47 | 2021-2023 | Verquvo, Belsomra |
| Pfizer INC. | $174.44 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $152.80 | 2021-2024 | Austedo Xr |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Lambert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.